Archive for the ‘Crispr’ Category

On Oct. 7, an amazing advancement for women occurred for the first time in history: Emmanuelle Charpentier and Jennifer A. Doudna, a duo of female scientists, received the Nobel Prize in Chemistry without a male contributor listed on the award. They were awarded this prize due to their research in genome editing with the tool called CRISPR. Whether you remember reading about CRISPR in AP Biology in high school or are actively involved with CRISPR as a chemistry or bioengineering student, what remains clear is that these two women paved the way for the next generation of female scientists, and for how genetic diseases will be cured.

The Point talked with a female professor and two female students via email about this advancement. Each had much to share about their experiences as women in this field. Heidi Woelbern, a biology professor at PLNU, uses CRISPR in her research. Olivia Owen and Kaitlyn Morgan are both biochemistry majors.

The Point: What is genome editing and how has Charpentier and Doudnas work changed the course of science in relation to DNA experiments?

Heidi Woelbern: CRISPR technology is revolutionary. The ability to edit genes within the genome is foundational to understanding what exactly they do. When I was in graduate school in the early 2000s, a graduate student might spend two years developing a mouse model in which a single gene was knocked out. For instance, if you were interested in diabetes, you might knock out one of the many genes thought to play a role in diabetes. You would then study the mouse to see if diabetes was ameliorated or then still persisted. With CRISPR technology, a knockout mouse model can be developed in about one month. The gene-editing capabilities are more precise, vastly cheaper and produce results in a fraction of the time.

Olivia Owen: The work of these two women with CRISPR is revolutionary. Its going to be the foundation for so many other scientific and medical breakthroughs, and its already being used in numerous ways to treat cancer and genetic diseases.

Kaitlyn Morgan: I am currently in genetics [class] right now and am learning about CRISPR. It really excited me after learning that these two women were the pioneers of developing the CRISPR model to influence new technological advances in treating disease by altering the genome.

TP: What was your initial reaction when you found out that Charpentier and Doudna had won this prize?

HW: I was thrilled to see this. I love that it was a team of women, working collaboratively, in different countries (Emmanuelle Charpentier was working in Europe, predominantly in Germany and Jennifer Doudna in the U.S.). They shared ideas, their new findings, and even their researchers. It appears (from the outside) to be very collaborative and productive. I love that they both are biochemists. There is so much to learn when one pairs the chemistry and behavior of molecules in isolation and then applies that knowledge into increasingly complex biological models

OO: My initial reaction to finding out that a duo of women won the Nobel prize was excitement. There are so few women in the biochemical engineering field that its so cool to have successful women in the field to look up to.

KM: My initial reaction when finding out that these two women won the Nobel prize in chemistry really motivated me. It reminded me that I am capable and smart enough to pursue a degree in science.

TP: What is your experience in either learning or interacting with CRISPR/genome-editing software?

HW: In collaboration with Dr. Dorrell (biology) and Dr. Jansma (chemistry) we have been working on mutating a gene thought to play a role in cervical cancer. Dr. Jansma has analyzed the E7 oncoprotein from the human papillomavirus. She has been able to determine altered chemical characteristics of E7 based upon some minor changes in the gene (and thus the protein). Using site directed mutagenesis, we are generating these same variants from Dr. Jansmas studies and introducing them into a biologically relevant system to determine if the chemistry can explain the biology. This project thus far has not utilized CRISPR technology. However, we certainly could utilize this technology in the future; especially if we wanted to move into an animal model system.

TP: Are there any female chemists or scientists who are role models for you?

OO: Growing up, I always loved Marie Curie because she was a brilliant chemist even when there were no other women in her field. With these recent advancements in CRISPR, its going to be exciting that young girls are going to have more female role models to look up to.

KM: Honestly, the two women [Jennifer Doudna and Emmanuelle Charpentier] are my role models. The scientific advancement of genome editing that these two women discovered I believe is going to impact the science world by ultimately changing the way doctors treat patients. Overall, these two women have reminded me to keep on working hard and staying focused on my path to pursuing my degree because anything is possible.

Jennifer A. Dounda said in an article from Omniscience, One of the problems in the biotech world is the lack of women in leadership roles, and Id like to see that change by walking the walk.

You can learn more about these women and this years Nobel Prize award ceremony through the official Nobel Prize YouTube channel.

Written By: Elaine Alfaro

Like Loading...

Read more from the original source:
Women in Science: Thoughts on the 2020 Nobel Prize in Chemistry - Loma Beat

A new business intelligence report released by HTF MI with title Global COVID-19 CRISPR Technology Market Insights by Application, Product Type, Competitive Landscape & Regional Forecast 2025 is designed covering micro level of analysis by manufacturers and key business segments. TheGlobal COVID-19 CRISPR Technology Market survey analysisoffers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing. Some of the key players profiled in the study are Thermo Fisher Scientific (United States), Merck KGaA (Germany), Genscript Biotech (United States), Integrated DNA Technologies, Inc. (United States), Horizon Discovery Group (United Kingdom), Agilent Technologies (United States), Cellecta, Inc. (United States), GeneCopoeia, Inc. (United States), New England Biolabs (United States) and Origene Technologies, Inc. (United States).

Whats keeping Thermo Fisher Scientific (United States), Merck KGaA (Germany), Genscript Biotech (United States), Integrated DNA Technologies, Inc. (United States), Horizon Discovery Group (United Kingdom), Agilent Technologies (United States), Cellecta, Inc. (United States), GeneCopoeia, Inc. (United States), New England Biolabs (United States) and Origene Technologies, Inc. (United States) Ahead in the Market? Benchmark yourself with the strategic moves and findings recently released by HTF MIGet Free Sample Report + All Related Graphs & Charts @:https://www.htfmarketreport.com/sample-report/2833424-global-covid-19-crispr-technology-market

Market Overview of Global COVID-19 CRISPR TechnologyIf you are involved in the Global COVID-19 CRISPR Technology industry or aim to be, then this study will provide you inclusive point of view. Its vital you keep your market knowledge up to date segmented by Applications [Application I, Application II], Product Types [Enzymes, Kits, gRNA, Libraries and Design Tools] and major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization according to your requirement.

This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth analysis of the major vendor/key players in the market along with impact of economic slowdown due to COVID.

Furthermore, the years considered for the study are as follows:Historical year 2014-2019Base year 2019Forecast period** 2020 to 2026 [** unless otherwise stated]

**Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product services of key players.

Enquire for customization in Report @:https://www.htfmarketreport.com/enquiry-before-buy/2833424-global-covid-19-crispr-technology-market

The titled segments and sub-section of the market are illuminated below:The Study Explore the Product Types of COVID-19 CRISPR Technology Market: Enzymes, Kits, gRNA, Libraries and Design Tools

Key Applications/end-users of Global COVID-19 CRISPR Technology Market: Application I, Application II

Top Players in the Market are: Thermo Fisher Scientific (United States), Merck KGaA (Germany), Genscript Biotech (United States), Integrated DNA Technologies, Inc. (United States), Horizon Discovery Group (United Kingdom), Agilent Technologies (United States), Cellecta, Inc. (United States), GeneCopoeia, Inc. (United States), New England Biolabs (United States) and Origene Technologies, Inc. (United States).

Region Included are: ** Confirmation on availability of data would be informed prior purchase

Important Features that are under offering & key highlights of the report: Detailed overview of COVID-19 CRISPR Technology market Changing market dynamics of the industry In-depth market segmentation by Type, Application etc Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape of COVID-19 CRISPR Technology market Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards COVID-19 CRISPR Technology market performance Market players information to sustain and enhance their footprint

Read Detailed Index of full Research Study at @https://www.htfmarketreport.com/reports/2833424-global-covid-19-crispr-technology-market

Major Highlights of TOC:Chapter One: Global COVID-19 CRISPR Technology Market Industry Overview1.1 COVID-19 CRISPR Technology Industry1.1.1 Overview1.1.2 Products of Major Companies1.2 COVID-19 CRISPR Technology Market Segment1.2.1 Industry Chain1.2.2 Consumer Distribution1.3 Price & Cost Overview

Chapter Two: Global COVID-19 CRISPR Technology Market Demand2.1 Segment Overview2.1.1 APPLICATION 12.1.2 APPLICATION 22.1.3 Other2.2 Global COVID-19 CRISPR Technology Market Size by Demand2.3 Global COVID-19 CRISPR Technology Market Forecast by Demand

Chapter Three: Global COVID-19 CRISPR Technology Market by Type3.1 By Type3.1.1 TYPE 13.1.2 TYPE 23.2 COVID-19 CRISPR Technology Market Size by Type3.3 COVID-19 CRISPR Technology Market Forecast by Type

Chapter Four: Major Region of COVID-19 CRISPR Technology Market4.1 Global COVID-19 CRISPR Technology Sales4.2 Global COVID-19 CRISPR Technology Revenue & market share

Chapter Five: Major Companies List

Chapter Six: Conclusion

Complete Purchase of Latest Version Global COVID-19 CRISPR Technology Market Study with COVID-19 Impact Analysis @https://www.htfmarketreport.com/buy-now?format=1&report=2833424

Key questions answered What impact does COVID-19 have made on Global COVID-19 CRISPR Technology Market Growth & Sizing? Who are the Leading key players and what are their Key Business plans in the Global COVID-19 CRISPR Technology market? What are the key concerns of the five forces analysis of the Global COVID-19 CRISPR Technology market? What are different prospects and threats faced by the dealers in the Global COVID-19 CRISPR Technology market? What are the strengths and weaknesses of the key vendors?

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]

Connect with us atLinkedIn|Facebook|Twitter

Follow this link:
CRISPR Technology Market Will Generate New Growth Opportunities in the upcoming year - Aerospace Journal

CRISPR and Cas Genes Market provides an in-depth insight into Sales and Trends Forecast: 2020-2025:

Global CRISPR and Cas Genes 2020 Report consists of important factors such as the latest trends, performance drivers, key players, revenue, growth rate and volume sales, and consumer insights. The most recent report by regal intelligence on global CRISPR and Cas Genes market analyses the impact of COVID 19 on the industry. The reports comprehend the global industry outlook in the light of the current market situation, trends, prominent players in the industry, and how these factors are expected to boost the CRISPR and Cas Genes market during the forecast period. The research study by regal intelligence analyses factors that are dynamic and will affect the CRISPR and Cas Genes market in the near future.

Global CRISPR and Cas Genes market competition by TOP MANUFACTURERS, with production, price, revenue (value) and each manufacturer including

CRISPR Therapeutics, AstraZeneca, Addgene, Caribou Biosciences, Inc., Cellectis, Editas Medicine, Inc., Egenesis, F. Hoffmann-La Roche Ltd., Horizon Discovery Group Plc, Genscrip, Danaher Corporation, Intellia Therapeutics, Inc., Lonza, Merck KGaA, New En

For Better Understanding Go With This Free Sample Report Enabled With Respective Tables and Figures( Get Instant 10% Discount ):https://www.eonmarketresearch.com/sample/72556

Global CRISPR and Cas Genes Market forecast to 2025 providing information such as company profiles, product picture, and specification, capacity, production, price, cost, revenue, and contact information. Upstream raw materials and equipment and downstream demand analysis are also carried out. The Global CRISPR and Cas Genes market trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Years Considered to Estimate the CRISPR and Cas Genes Market Size:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year: 2020-2025

Region Coverage (Regional Production, Demand & Forecast by Countries, etc.):

CRISPR and Cas Genes Market regional analysis covers the following regions North America, Europe, Asia-Pacific, South America, Middle East & Africa.

Buy This Premium Report: https://www.eonmarketresearch.com/buy/72556

Product Type Coverage CRISPR and Cas Genes Market Size & Forecast, Major Company of Product Type, etc.):

General Type

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including

Biomedical

Some of the key questions answered in this report:

Any Questions? Feel Free To Enquire Here. We will Put You On The Right Path: https://www.eonmarketresearch.com/enquiry/72556

Major Point of TOC:

Part I CRISPR and Cas Genes Industry Overview

Chapter One:CRISPR and Cas Genes Industry Overview

Chapter Two:CRISPR and Cas Genes Up and Down Stream Industry Analysis

Part II Asia CRISPR and Cas Genes Industry (The Report Company Including the Below Listed But Not All)

Chapter Three:Asia CRISPR and Cas Genes Market Analysis

Chapter Four:2015-2020 Asia CRISPR and Cas Genes Productions Supply Sales Demand Market Status and Forecast

Chapter Five:Asia CRISPR and Cas Genes Key Manufacturers Analysis

Chapter Six:Asia CRISPR and Cas Genes Industry Development Trend

Part III North American CRISPR and Cas Genes Industry (The Report Company Including the Below Listed But Not All)

Chapter Seven:North American CRISPR and Cas Genes Market Analysis

Chapter Eight:2015-2020 North American CRISPR and Cas Genes Productions Supply Sales Demand Market Status and Forecast

Chapter Nine:North American CRISPR and Cas Genes Key Manufacturers Analysis

Chapter Ten:North American CRISPR and Cas Genes Industry Development Trend

Part IV Europe CRISPR and Cas Genes Industry Analysis (The Report Company Including the Below Listed But Not All)

Chapter Eleven:Europe CRISPR and Cas Genes Market Analysis

Chapter Twelve:2015-2020 Europe CRISPR and Cas Genes Productions Supply Sales Demand Market Status and Forecast

Chapter Thirteen:Europe CRISPR and Cas Genes Key Manufacturers Analysis

Chapter Fourteen:Europe CRISPR and Cas Genes Industry Development Trend

Part V CRISPR and Cas Genes Marketing Channels and Investment Feasibility

Chapter Fifthteen:CRISPR and Cas Genes Marketing Channels Development Proposals Analysis

Chapter Sixteen:Development Environmental Analysis

Chapter Seventeen:CRISPR and Cas Genes New Project Investment Feasibility Analysis

Part VI Global CRISPR and Cas Genes Industry Conclusions

Chapter Eighteen:2015-2020 Global CRISPR and Cas Genes Productions Supply Sales Demand Market Status and Forecast

Chapter Nineteen:Global CRISPR and Cas Genes Industry Development Trend

*** Thanks for reading this article; you can also get region wise report version like North America, Asia-Pacific, Europe, South America, Middle East Africa. ***

About Us:

Eon Market Research(EMR) is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. Eon Market Research offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Get in Touch with Us :

Eon Market Research

Phone: +1 703 879 7090

Email: [emailprotected]

See the original post:
CRISPR and Cas Genes Market Insight | Strategic Industry Evolutionary Analysis Focus on Leading Key Players and Revenue Growth Analysis by Forecast To...

CRISPR Technology Marketanalysis is provided for the Global market including development trends by regions, competitive analysis of CRISPR Technologymarket. CRISPR TechnologyIndustryreport focuses on the major drivers and restraints for the key players.

According to the CRISPR Technology Market report, the global market is expected to witness a relatively higher growth rate during the forecast period. The report provides key statistics on the market status of Global and Chinese CRISPR Technology Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry

Major Key Contents Covered in CRISPR TechnologyMarket:

Ask for Sample PDF for in-depth information on CRISPR TechnologyMarket Report@https://inforgrowth.com/sample-request/6475179/crispr-technology-market

Then, the report explores the international major players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2015-2019 market shares for each company.

After the basic information, the report sheds light on the production. Production plants, their capacities, global production, and revenue are studied. Also, the CRISPR TechnologyMarket Sales growth in various regions and R&D status are also covered.

Through the statistical analysis, the report depicts the global and Chinese total market of CRISPR Technologymarket including capacity, production, production value, cost/profit, supply/demand, and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

CRISPR TechnologyMarket Report Segmentation:

Product Type:

Application:

Key Players:

Get Chance of 20% Extra Discount, If your Company is Listed in Above Key Players List;https://inforgrowth.com/discount/6475179/crispr-technology-market

Region Analysis:The report then estimates 2020-2026 market development trends of CRISPR Technologymarket. Analysis of upstream raw materials, downstream demand and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of CRISPR Technologymarket before evaluating its feasibility.

Table and Figures Covered in This Report:

Then, the report focuses on global major leading CRISPR TechnologyMarket players with information such as company profiles, product picture, and specification, capacity, production, price, cost, revenue, and contact information. Upstream raw materials and downstream consumers analysis is also carried out. Whats more, the Global CRISPR TechnologyMarket development trends and marketing channels are analyzed.

In nutshell, the CRISPR Technology Market feasibility of new investment projects is assessed, and overall research conclusions are offered. In a word, the CRISPR TechnologyMarket report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the Market Sales.

Enquire before Purchase this report athttps://inforgrowth.com/enquiry/6475179/crispr-technology-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898

Original post:
CRISPR Technology Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top Players:...

The Office of Research and the School of Medicine had planned to introduce their Oct. 30 speaking guest as a professor and the founder and director of the Innovative Genomics Institute at UC Berkeley, and a CRISPR pioneer.

Since being booked for the Distinguished Speaker Series in Research and Innovation, however, Jennifer Doudna has added a new title: Nobel laureate.

She and Emmanuelle Charpentier, director of the Max Planck Institute for Infection Biology, won the Nobel Prize in chemistry Oct. 7 for their co-development of CRISPR-Cas9, a genome editing tool that has revolutionized biomedicine and agriculture.

Whats CRISPR? Jennifer Doudna explains in a Radiolab podcast.

Doudna became the first woman on the UC Berkeley faculty to win a Nobel, and she and Charpentier are the first women to share a Nobel in the sciences.

Doudnas topic for her UC Davis talk is CRISPR and Coronavirus.

UC Davis Healths Ralph Green, distinguished professor in the Department of Pathology and Laboratory Medicine, and medical director of UC Davis Diagnostics, recently collaborated with Doudna and others on a project to set up COVID-19 testing for UC Berkeley and the surrounding community and Green is helping with a similar project at UC Davis.

I had the good fortune to get to know Jennifer Doudna through my interaction with her group when they turned their skills and knowledge to setting up, at remarkable speed, a pop-up, PCR-based test for SARS-CoV-2 during the early days of the COVID-19 pandemic when the country was scrambling to meet the need for more testing, Green said.

I have to say that it has been a singular pleasure and privilege for me to interact with Jennifer Doudna and her colleagues.

CRISPR-Cas9 genetic engineering technology enables scientists to change or remove genes quickly and with great precision. Labs worldwide have redirected their research programs to incorporate this new tool, creating a CRISPR revolution with huge implications across biology and medicine.

Doudna is a leader in public discussion of the ethical implications of genome editing for human biology and societies. She advocates for thoughtful approaches to the development of policies around the use of CRISPR-Cas9.

Follow Dateline UC Davis on Twitter.

See the article here:
'CRISPR and Coronavirus': Hear From Nobel Winner Jennifer Doudna - UC Davis

From the beginning, Pfizer CEO Albert Bourla eschewed government funding for his Covid-19 vaccine work with BioNTech, willing to take all the $2 billion-plus risk of a lightning-fast development campaign in exchange for all the rewards that could fall its way with success. And now that the pharma giant has seized a solid lead in the race to the market, those rewards loom large.

SVB Leerinks Geoff Porges has been running the numbers on Pfizers vaccine, the mRNA BNT162b2 program that the German biotech partnered on. And he sees a $3.5 billion peak in windfall revenue next year alone. Even after the pandemic is brought to heel, though, Porges sees a continuing blockbuster role for this vaccine as people around the world look to guard against a new, thoroughly endemic virus that will pose a permanent threat.

Unlock this story instantly and join 92,200+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Read the rest here:
UPDATED: CRISPR Therapeutics gets a snapshot of off-the-shelf CAR-T success in B-cell malignancies marred by the death of a patient - Endpoints News

Its been a good year for Intellia: One of its founders, Jennifer Doudna, Ph.D., nabbed the Nobel Prize in Chemistry for her CRISPR research.

Now, the biotech she helped build is putting that to work, saying it now plans the worlds first clinical trial for asingle-course therapy that potentially halts and reverses a condition known as hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN).

This genetic disorder occurs when a person is born with a specific DNA mutation in the TTR gene, which causes the liver to produce a protein called transthyretin (TTR) in a misfolded form and build up in the body.

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

hATTR can manifest as polyneuropathy (hATTR-PN), which can lead to nerve damage, or cardiomyopathy (hATTR-CM), which involves heart muscle disease that can lead to heart failure.

This disorder has seen a lot of interest in recent years, with an RNAi approach from Alnylam seeing an approval for Onpattro a few years back, specifically for hATTR in adults with damage to peripheral nerves.

Ionis Pharmaceuticals and its rival RNAi drug Tegsedi also saw an approval in 2018 for a similar indication.

They both battle with Pfizers older med tafamidis, which has been approved in Europe for years in polyneuropathy, and the fight could spread to the U.S. soon.

The drug, now marketed as Vyndaqel and Vyndamax, snatched up an FDA nod last May to treat both hereditary and wild-type ATTR patients with a heart condition called cardiomyopathy.

While coming into an increasingly crowed R&D area, Intellia is looking for a next-gen approach, and has been given the go-ahead by regulators ion the U.K, to start a phase 1 this year.

The idea is for Intellias candidate NTLA-2001, which is also partnered with Regeneron, to go beyond its rivals and be the first curative treatment for ATTR.

By applying the companys in vivo liver knockout technology, NTLA-2001 allows for the possibility of lifelong transthyretin (TTR) protein reduction after a single course of treatment. If this works, this could in essence cure patients of the their disease.

The 38-patient is set to start by years end.

Starting our global NTLA-2001 Phase 1 trial for ATTR patients is a major milestone in Intellias mission to develop medicines to cure severe and life-threatening diseases, said Intellias president and chief John Leonard, M.D.

Our trial is the first step toward demonstrating that our therapeutic approach could have a permanent effect, potentially halting and reversing all forms of ATTR. Once we have established safety and the optimal dose, our goal is to expand this study and rapidly move to pivotal studies, in which we aim to enroll both polyneuropathy and cardiomyopathy patients."

Continue reading here:
Intellia to kick-start first single-course 'curative' CRISPR shot, as it hopes to beat rivals Alnylam, Ionis and Pfizer - FierceBiotech

In a study published [September 21] in theNature Biomedical Engineeringjournal, the researchers said they usedCRISPRCas9 and a combination of other genetic technologies to inactivate porcine endogenous retroviruses (PERVs), a group of viruses that could be dangerous to humans, while also enhancing the pigs immunological and blood-coagulation compatibility with humans, which could reduce the risk of rejection by organ recipients.

The engineered pigs exhibited normal physiology, fertility and transmission of the edited genes to their offspring, according to the paper.

Transplants from pigs have long been investigated as a solution to the global shortage of human organs for patients with organ failure, for reasons such as the size of their organs similar enough to those of humans and their relatively short maturity period of about six months.

The risks of organ rejection due to the biological incompatibility of pig organs with human bodies and of transmitting PERVs have limited the clinical applicability of such transplants, but advancements in gene-editing technology have given researchers new hope.

George Church, one of the authors from Harvard Medical School and a co-founder of Hangzhou-based Qihan Bio, was quoted by Chinese news agency Xinhua as saying that if the technology used can be further verified in future research, it could help alleviate the global shortage of human organs to a large extent.

Read the original post

Read more here:
CRISPR has brought pig-to-human organ transplants to the cusp of reality - Genetic Literacy Project

The global CRISPR Cas9 Industry Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global CRISPR Cas9 Industry market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global CRISPR Cas9 Industry market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global CRISPR Cas9 Industry market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global CRISPR Cas9 Industry market.

The research report on CRISPR Cas9 Industry market elaborates on the major trends defining the industry growth with regards to the regional terrain and competitive scenario. The document also lists out the limitations & challenges faced by industry participants alongside information such as growth opportunities. Apart from this, the report contains information regarding the impact of COVID-19 pandemic on the overall market outlook.

Key insights from COVID-19 impact analysis:

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/228075

An overview of regional landscape:

Additional information from the CRISPR Cas9 Industry market report:

Table of Contents

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/228075

Visit link:
CRISPR Cas9 Industry Market Overview, Environmental Analysis and Forecast to 2025 - Express Journal

A researcher observes the process of genetic scissors in a laboratory in Berlin (Germany). (GREGOR FISCHER / DPA)

The genetic scissors, called Crispr-Case 9 discovered almost ten years ago, are actually genetic code scissors. They make it possible to separate two strands of DNA and replace or delete a gene. When American and French scientists Jennifer Doudna and Emmanuelle Charpentier made this discovery, it paved the way for much research. Today, American, European and Australian scientists are meeting in videoconference to take stock of their progress.

For example, Crispr is making great progress in research into gene therapy. Today, this technique makes it possible to treat people with Duchenne muscular dystrophy, one of the genetic diseases often mentioned during the Telethon. Inserm was also able to reactivate a gene to fight against sickle cell anemia: a blood disease linked again to a genetic problem. Moreover, the company eGenesis works on pigs free of viruses dangerous to humans. The animals would then become perfect organ donors for patients awaiting transplants of the heart, pancreas, etc.

The Crispr technique has developed in many laboratories around the world and two years ago a Chinese researcher, He Jiankui, caused a scandal after announcing that he had used it to create, through in vitro fertilization, two GMO babies resistant to HIV whose father was a carrier. According to a survey, in the MIT Technology Review, the researcher forced the hand of parents who saw in this genetic manipulation the only way to have children without risk. In addition, today it is not known how babies are doing and what other genetic consequences the use of Crispr has had on them. The researcher is still under house arrest in China.

Emmanuelle Charpentier in an interview on point obviously criticizes the failure to respect ethical criteria for the use of its scissors applied to research for humans. On the other hand, she does not share the doubts of peasant and environmental associations on plants modified by Crispr-Cas 9 and considered as GMOs in Europe. For her, her innovation makes it possible to boost a plant gene, to reproduce in an accelerated manner what can happen in nature. Its not like creating mutant plants with a gene that comes from other species.

Applied to theAgriculture, Crispr-Cas 9 makes it possible to create allergen-free peanuts, gluten-free wheat, more drought-resistant rice, but also to remove the horns of cows or to herd only males. Crispr-Cas 9 therefore asks even more to meditate on Rabelais sentence: Science without consciousness is nothing but the ruin of the soul.

See the original post:
Advances and concerns raised by Crispr-Cas 9, the genetic scissors - Pledge Times

Chemistry Nobel Prize award recipients Jennifer A. Doudna and Emmanuelle Charpentier have joined the ranks of Marie Curie, Frances Arnold, Ada E. Yonath and Dorothy Crowfoot Hodgkin.J.L. Cereijido/EPA

THE Royal Swedish Academy of Sciences yesterday awarded the 2020 Nobel Prize in Chemistry to Emmanuelle Charpentier and Jennifer Doudna for their work on CRISPR, a method of genome editing.

A genome is the full set of genetic instructions that determine how an organism will develop. Using CRISPR, researchers can cut up DNA in an organisms genome and edit its sequence.

CRISPR technology is a powerhouse for basic research and is also changing the world we live in. There are thousands of research papers published every year on its various applications.

These include accelerating research into cancers, mental illness, potential animal to human organ transplants, better food production, eliminating malaria-carrying mosquitoes and saving animals from disease.

Charpentier is the director at the Max Planck Institute for Infection Biology in Berlin, Germany and Doudna is a professor at the University of California, Berkeley. Both played a crucial role in demonstrating how CRISPR could be used to target DNA sequences of interest.

Read more:Why more women dont win science Nobels

CRISPR technology is adapted from a system that is naturally present in bacteria and other unicellular organisms known as archaea.

This natural system gives bacteria a form of acquired immunity. It protects them from foreign genetic elements (such as invading viruses) and lets them remember these in case they reappear.

Like most advances in modern science, the discovery of CRISPR and its emergence as a key genome editing method involved efforts by many researchers, over several decades.

In 1987, Japanese molecular biologist Yoshizumi Ishino and his colleagues were the first to notice, in E. coli bacteria, unusual clusters of repeated DNA sequences interrupted by short sequences.

Spanish molecular biologist Francisco Mojica and colleagues later showed similar structures were present in other organisms and proposed to call them CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats.

In 2005, Mojica and other groups reported the short sequences (or spacers) interrupting the repeats were derived from other DNA belonging to viruses.

Evolutionary biologists Kira Makarova, Eugene Koonin and colleagues eventually proposed CRISPR and the associated Cas9 genes were acting as the immune mechanism. This was experimentally confirmed in 2007 by Rodolphe Barrangou and colleagues.

The CRISPR-associated genes, Cas9, encode a protein that cuts DNA. This is the active part of the defence against viruses, as it destroys the invading DNA.

In 2012, Charpentier and Doudna showed the spacers acted as markers that guided where Cas9 would make a cut in the DNA. They also showed an artificial Cas9 system could be programmed to target any DNA sequence in a lab setting.

This was a groundbreaking discovery which opened the door for CRISPRs wider applications in research.

In 2013, for the first time, groups led by American biochemist Feng Zhang and geneticist George Church reported genome editing in human cell cultures using CRISPR-Cas9. It has since been used in countless organisms from yeast to cows, plants and corals.

Today, CRISPR is the preferred gene-editing tool for thousands of researchers.

Humans have altered the genomes of species for thousands of years. Initially, this was through approaches such as selective breeding.

However, genetic engineering the direct manipulation of DNA by humans outside of breeding and mutations has only existed since the 1970s.

CRISPR-based systems fundamentally changed this field, as they allow for genomes to be edited in living organisms cheaply, with ease and with extreme precision.

CRISPR is currently making a huge impact in health. There are clinical trials on its use for blood disorders such as sickle cell disease or beta-thalassemia, for the treatment of the most common cause of inherited childhood blindness (Leber congenital amaurosis) and for cancer immunotherapy.

CRISPR also has great potential in food production. It can be used to improve crop quality, yield, disease resistance and herbicide resistance.

Used on livestock, it can lead to better disease resistance, increased animal welfare and improved productive traits that is, animals producing more meat, milk or high-quality wool.

A number of challenges to the technology remain, however. Some are technical, such as the risk of off-target modifications (which happen when Cas9 cuts at unintended locations in the genome).

Other problems are societal. CRISPR was famously used in one of the most controversial experiments of recent years.

Read more:Why we need a global citizens assembly on gene editing

Chinese biophysicist He Jiankui unsuccessfully attempted to use the technology to modify human embryos and make them resistant to HIV (human immunodeficiency virus). This led to the birth of twins Lulu and Nana.

We need a broad and inclusive discussion on the regulation of such technologies especially given their vast applications and potential.

To quote CRISPR researcher Fyodor Urnov, Charpentier and Doudnas work really has changed everything.

Dimitri Perrin, Senior Lecturer, Queensland University of Technology

This article is republished from The Conversation under a Creative Commons license. Read the original article.

See the original post:
What is CRISPR, the gene editing technology that won the Chemistry Nobel prize? - Grain Central

As we know, COVID-19 is causing large scale loss of life and severe human suffering. With the pandemic spreading across the globe, researchers are racing against the clock to develop diagnostic tools, vaccines and treatments. Recently, WHO has launched a Solidarity clinical trial to assess relative effectiveness of four potential drugs against COVID-19. Further, there are close to 40 clinical trials of vaccines are ongoing, however, as per experts, it may take more than a year to develop a vaccine.

In order to enhance COVID-19 drug discovery and develop rapid testing kits, various academic institutes, non-profit institutes, scientific pioneers and biopharmaceutical companies have also been leveraging benefits of CRISPR technology.

For more Insights Click under

CRISPR Can be a Solution to Address the COVID-19 Pandemic

The CRISPR / Cas9 system has revolutionized the field of genetic engineering. It enables researchers to alter the genomes of a range of organisms with relative ease. Currently, it has emerged as a promising tool that is used extensively for editing genomes and for the development of novel treatment options. CRISPR is popularly known as search engine for biology, as it has emerged as a location finder, rather than site specific cleavage tool. The figure below highlights the key potential areas and benefits of CRISPR in order to fight against novel coronavirus.

Rapid and Economical Diagnostic Tests

Presently, COVID-19 testing capacity is limited by a number of factors, such as requirements for complex procedures, need for laboratory instrumentation, and dependence on limited supplies. Therefore, there is an urgent need for rapid detection kits. CRISPR has been explored by scientists for diagnosis of infectious diseases. The underlying mechanism involves binding of guide RNA with a protein of Cas family which cuts the target and shreds the nearby RNA or DNA. When CRISPR hits a target, the reporter molecule releases a fluorescent signal. This is further analysed by paper tests dipped into a patient sample, such as blood, urine, or saliva, which further shows up as a line on the testing strip. Researchers have been utilizing CRISPR-based tools and technologies to detect RNA of virus in patient samples. Sherlock Biosciences has already made history, as it received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its Sherlock CRISPR SARS-CoV-2 kit for the detection of the virus that causes COVID-19. The kit is designed for use in laboratories and can provide results within an hour. The company claims that more than 1 million tests can be performed within a week.

Enhancing Drug Discovery

CRISPR technology aids in the study of interaction of virus with human cells. This enables the generation of appropriate cell models for faster discovery of new potential treatment options, or identification of an existing drug combination that may provide a treatment solution. For instance, researchers are exploring molecular mechanisms of the novel virus by utilizing CRISPR technology, which can ultimately assist in identifying potential drug combinations.

CRISPR-based COVID-19 Therapy

Researchers at Stanford University have been working on the development of a gene targeting anti-viral agent against COVID-19, using PAC-MAN technology. The technology has been modified to be used against the deadly virus. It consists of a virus-killing enzyme, such as Cas13 and a guide RNA, which commands Cas13 to destroy specific nucleotide sequences in the coronaviruss genome. Based on several studies, it has been revealed that PAC-MAN has the ability to neutralize the coronavirus and stop it from replicating inside cells. Based on information available, work is currently ongoing, and researchers are finding a solution to deliver this technology to lung cells. Multiple delivery methods are currently under evaluation.

A lot of companies are currently active in providing CRISPR-based genome engineering services. To get a detailed information on the key players, recent developments, and the likely market evolution.

For more Insights Click under

CRISPR Can be a Solution to Address the COVID-19 Pandemic

You may also be interested in the following titles:

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If youd like help with your growing business needs, get in touch at [emailprotected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[emailprotected]

See the rest here:
CRISPR Can be a Solution to Address the COVID-19 Pandemic | Roots Analysis - Eurowire

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Crispr Therapeutics AG (CRSP). The companys shares closed last Wednesday at $94.30.

According to TipRanks.com, Prasad is a 5-star analyst with an average return of 13.4% and a 53.9% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.

Currently, the analyst consensus on Crispr Therapeutics AG is a Strong Buy with an average price target of $95.88, implying a 5.1% upside from current levels. In a report released today, Needham also assigned a Buy rating to the stock with a $105.00 price target.

See todays analyst top recommended stocks >>

The company has a one-year high of $111.90 and a one-year low of $32.30. Currently, Crispr Therapeutics AG has an average volume of 870.1K.

Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

View post:
William Blair Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP) - Smarter Analyst

CRISPR And CRISPR-Associated (Cas) Genes Market report would come handy to understand the competitors in the market and give an insight into sales, volumes, revenues in the CRISPR And CRISPR-Associated (Cas) Genes Industry & will also assists in making strategic decisions. The report also helps to decide corporate product & marketing strategies. It reduces the risks involved in making decisions as well as strategies for companies and individuals interested in the CRISPR And CRISPR-Associated (Cas) Genes industry. Both established and new players in CRISPR And CRISPR-Associated (Cas) Genes industries can use the report to understand the CRISPR And CRISPR-Associated (Cas) Genes market.

In Global Market, the Following Companies Are Covered:

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14841056

Analysis of the Market:

Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of spacer DNA from previous exposures to a bacteriophage virus or plasmid.

The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.

CRISPR And CRISPR-Associated (Cas) Genes industry is relatively concentrated, manufacturers are mostly in the Europe and North America. Among them, North America region accounted for more than 45.70% of the total market of global CRISPR And CRISPR-Associated (Cas) Genes.

The global CRISPR And CRISPR-Associated (Cas) Genes market is valued at 713.8 million USD in 2020 is expected to reach 7696.7 million USD by the end of 2026, growing at a CAGR of 40.0% during 2021-2026.

This report focuses on CRISPR And CRISPR-Associated (Cas) Genes volume and value at the global level, regional level and company level. From a global perspective, this report represents overall CRISPR And CRISPR-Associated (Cas) Genes market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan et

CRISPR And CRISPR-Associated (Cas) Genes Market Breakdown by Types:

CRISPR And CRISPR-Associated (Cas) Genes Market Breakdown by Application:

Critical highlights covered in the Global CRISPR And CRISPR-Associated (Cas) Genes market include:

The information available in the CRISPR And CRISPR-Associated (Cas) Genes Market report is segmented for proper understanding. The Table of contents contains Market outline, Market characteristics, Market segmentation analysis, Market sizing, customer landscape & Regional landscape. For further improving the understand ability various exhibits (Tabular Data & Pie Charts) has also been used in the CRISPR And CRISPR-Associated (Cas) Genes Market report.

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14841056

Reasons for Buy CRISPR And CRISPR-Associated (Cas) Genes Market Report:

In the end, CRISPR And CRISPR-Associated (Cas) Genes Industry report provides the main region, market conditions with the product price,profit, capacity, production, supply, demand and market growth rateand forecast etc. This report also Present newproject SWOT analysis,investment feasibility analysis, andinvestment return analysis.

Contact Us:

Name: Mr. Ajay More

Email: [emailprotected]

Organization: 360 Market Updates

Phone: +14242530807 / + 44 20 3239 8187

Global Shortening Market Size in 2020 (New Report): Manufacturers Data, Opportunity, Import Export Scenario, Application, Showing Impressive Growth by 2026

Swimwear and Beachwear Market Size 2020-2026 Research Report by Key Companies, Future Trend, Pipeline Projects, Product, Application, Growth and Regional Forecasts

Trunking System Market Size 2020 : Business Opportunity, SWOT Analysis, Applications, Trends and Forecast to 2026 Research Reportby360marketupdates

Global Acraldehyde Market 2020 Industry Analysis, Size, Share, Trends, Market Demand, Growth, Opportunities and Showing Impressive Growth by 2026

Medical Robotic Systems Market Size 2020-2026 Industry Trends, Size, Segments, Competitors Classification, Growth, Up and Down Stream Industry Analysis and Forecast

Solid of Sodium Methylate Market Size, Growth Opportunities, Emerging Technologies, Trends,Growth, Segments, Landscape and Demandby usingForecast to 2026 Research Reportvia360marketupdates

Go here to read the rest:
CRISPR And CRISPR-Associated (Cas) Genes Market 2020 to Flourish with an Impressive CAGR of XX% in the year 2026, Market Size & Growth with...

Report is a detailed study of the CRISPR and CAS Gene market, which covers all the essential information required by a new market entrant as well as the existing players to gain a deeper understanding of the market. The primary objective of this research report named CRISPR and CAS Gene market is to help making reliable strategic decisions regarding the opportunities in CRISPR and CAS Gene market.

Major Market Players with an in-depth analysis:

Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.

Request Free Sample Copy of CRISPR and CAS Gene Market Research [emailprotected]:https://www.coherentmarketinsights.com/insight/request-sample/2598

The Global CRISPR and CAS Gene Market segments and Market Data Break Down are illuminated below:

By Product Type:Vector-based CasDNA-free CasGlobal CRISPR and CAS Gene Market, By Application:Genome EngineeringDisease modelsFunctional GenomicsKnockdown/activationOther Applications

The CRISPR and CAS Gene market report offers the current state of the market around the world. The report starts with the market outline and key of the CRISPR and CAS Gene market which assumes a significant job for clients to settle on the business choice. It additionally offers the key focuses to upgrade the development in the CRISPR and CAS Gene market. Some fundamental ideas are likewise secured by reports, for example, item definition, its application, industry esteem chain structure and division which help the client to break down the market without any problem. Also, the report covers different factors, for example, arrangements, efficient and innovative which are affecting the CRISPR and CAS Gene business and market elements.

Download Sample Report of CRISPR and CAS Gene Market Report 2020 (Coronavirus Impact Analysis on CRISPR and CAS Gene Market)

Competitive Analysis has been done to understand overall market which will be helpful to take decisions. Major players involved in the manufacture of CRISPR and CAS Gene product has been completely profiled along with their SWOT. Some of the key players include Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc. It helps in understanding their strategy and activities. Business strategy described for every company helps to get idea about the current trends of company. The industry intelligence study of the CRISPR and CAS Gene market covers the estimation size of the market each in phrases of value (Mn/Bn USD) and volume (tons). Report involves detailed chapter on COVID 19 and its impact on this market. Additionally, it involves changing consumer behavior due to outbreak of COVID 19.

Further, report consists of Porters Five Forces and BCG matrix as well as product life cycle to help you in taking wise decisions. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Regional Analysis for CRISPR and CAS Gene

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample):https://www.coherentmarketinsights.com/insight/request-discount/2598

Chapters Define in TOC (Table of Content) of the Report:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation

Overview

Chapter 2: COVID Impact

Chapter 3: Market Competition by Manufacturers

Chapter 4: Production by Regions

Chapter 5: Consumption by Regions

Chapter 6: Production, By Types, Revenue and Market share by Types

Chapter 7: Consumption, By Applications, Market share (%) and Growth Rate by

Applications

Chapter 8: Complete profiling and analysis of Manufacturers

Chapter 9: Manufacturing cost analysis, Raw materials analysis, Region-wise

Manufacturing expenses

Chapter 10: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 11: Marketing Strategy Analysis, Distributors/Traders

Chapter 12: Market Effect Factors Analysis

Chapter 13: Market Forecast

Chapter 14: CRISPR and CAS Gene Research Findings and Conclusion, Appendix, methodology and data source

DOWNLOAD FREE SAMPLE [emailprotected]:https://www.coherentmarketinsights.com/insight/request-sample/2598

The qualitative contents for geographical analysis will cover market trends in each region and country which includes highlights of the key players operating in the respective region/country, PEST analysis of each region which includes political, economic, social and technological factors influencing the growth of the market. The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2020 to 2027.

About Us:

Coherent Market Insightsis a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts Us: +1-206-701-6702Email: [emailprotected]Web: https://www.coherentmarketinsights.com/

**********Download the Entire Report*************************************************

https://www.coherentmarketinsights.com/market-insight/crispr-and-cas-gene-market-2598

Go here to read the rest:
Covid-19 Impact On CRISPR and CAS Gene Market Study: An Emerging Hint of Opportunity Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC,...

Share this Article

You are free to share this article under the Attribution 4.0 International license.

New generation CRISPR technology could pave the way for therapeutics to treat inherited retina diseases, researchers report.

In this proof-of-concept study, we provide evidence of the clinical potential of base editors for the correction of mutations causing inherited retinal diseases and for restoring visual function, says Krzysztof Palczewski, chair and a professor in the Gavin Herbert Eye Institutes ophthalmology department at the University of California, Irvine School of Medicine. Our results demonstrate the most successful rescue of blindness to date using genome editing.

Inherited retinal diseases (IRDs) are a group of blinding conditions caused by mutations in more than 250 different genes. Previously, there was no avenue available for treating these devastating blinding diseases. Recently, the FDA approved the first gene augmentation therapy for Leber congenital amaurosis (LCA), a common form of IRD which originates during childhood.

As an alternative to gene augmentation therapy, we applied a new generation of CRISPR technology, referred to as base editing as a treatment for inherited retinal diseases, says first author Susie Suh, assistant specialist in the ophthalmology department.

We overcame some of the barriers to the CRISPR-Cas9 system, such as unpredictable off-target mutations and low editing efficiency, by utilizing cytosine and adenine base editors (CBE and ABE). Use of these editors enabled us to correct point mutations in a precise and predictable manner while minimizing unintended mutations that could potentially cause undesirable side effects, says co-first author Elliot Choi, also an assistant specialist in the ophthalmology department.

Using an LCA mouse model harboring a clinically relevant pathogenic mutation in the Rpe65 gene, the researchers successfully demonstrated the therapeutic potential of base editing for the treatment of LCA and by extension other inherited blinding diseases.

Among other results, the base editing treatment restored retinal and visual function in LCA mice to near-normal levels. Base editing was developed at the Broad Institute of MIT and Harvard in the lab of David Liu.

After receiving treatment, the mice in our study could discriminate visual changes in terms of direction, size, contrast, and spatial and temporal frequency, says Palczewski.

These results are extremely encouraging and represent a major advance towards the development of treatments for inherited retinal diseases.

Gene therapy approaches to treating inherited retinal diseases are of special interest given the accessibility of the eye, its immune-privileged status, and the successful clinical trials of RPE65 gene augmentation therapy that led to the first US Food and Drug Administration-approved gene therapy.

Now, as demonstrated in this study, base-editing technology can provide an alternative treatment model of gene augmentation therapy to permanently rescue the function of a key vision-related protein disabled by mutations.

The new paper appears in Nature Biomedical Engineering.

Support for the research came from the National Institutes of Health; the Research to Prevent Blindness Stein Innovation Award; Fight for Sight; the Eye and Tissue Bank Foundation (Finland); the Finnish Cultural Foundation; the Orion Research Foundation; the Helen Hay Whitney Foundation; US Department of Veterans Affairs; and a Research to Prevent Blindness unrestricted grant to the Department of Ophthalmology, University of California, Irvine.

Source: UC Irvine

The rest is here:
Therapy restores vision in mice with retina disease - Futurity: Research News

Here are some events that caught our eye, either because of their nod to current events or their unique nature. But really, you'll want to peruse the schedule yourself as the options are seemingly endless and you can customize your search to your interests and age range. Also, you must register (it's free!) to see full details of each event.

Events That Take You Outside

Interactive Bird Scavenger Hunt

If you've ever wanted to get into birding but find the Sibley guides overwhelming, this session is for you. Download the scavenger hunt card and join other aspiring ornithologists in observing local birds and their behavior.

Share the Night Sky

What do you get when you mix a radio show and a planetary show? This show features San Franciscos Urban Astronomer Paul Salazar and KPOO's DJ Marilynn. Tune in for a guided tour of the night sky in real time.

Events for Big Thinkers

Astronomy Talks: Quantum Mechanics vs General Relativity: Clash of the Titans

Join a discussion about unifying the two theories and creating "a single theory that describes the entire Universe." Doesn't get much bigger picture than that, now, does it?

CRISPR, Sickle Cell Disease, and Society: A VR Explainer and Ethics Discussion

Explore how CRISPR genome editing may be used to repair the sickle cell mutation. See a virtual reality tour of the human body, and a talk on health disparities in the U.S. and the ethics of CRISPR.

N ~ 1: Alone in the Milky Way

Dr. Pascal Lee, a planetary scientist who works at the Mars Institute, the SETI Institute and the Haughton-Mars Project at the NASA Ames Research Center, makes the case that "we might be it, in the vastness of our galaxy."

Events for the Foodies (or the Science-Reluctant)

The Science of Sundaes

You had me at ice cream scientist. Dr. Maya Warren will teach families how to make their own sweet treats at home and discuss her career as a "real-life ice cream scientist"!

The Science Behind Hand-Pulled Noodles

Members of the Stanford Polymer Collective will make a basic dough and explain how additives like oil, water and salt change the dough's mechanical properties. Participants are encouraged to follow along at home and decide which dough makes the best hand-pulled noodles.

Events for Climate Activists

Bay Area Youth Climate Activism Panel

Get inspired and learn from the young people in the Bay Area who are trying to save our ecosystems.

Wetland Protectors: Our First Line of Defense

Save the Bay will demonstrate why tidal marshlands and native plants are key to flood protection for bayside communities threatened by climate change.

Events at the Frontline of the Pandemic

Behind the Scenes at a COVID-19 Diagnostic Testing Center

You ever wonder what happens after the nose and throat swabs? We'll go inside a lab that's working with UCSF on COVID-19 testing. "Follow a sample from its arrival at the lab, through RNA extraction and amplification, to the end result to reveal if it is positive or negative for the virus."

Exploring Connections Between Cancer and COVID-19

Talk to researchers from the UCSF Cancer Cell Map Initiative (CCMI) and Quantitative Biology Institute Coronavirus Research Group (QBI-QCRG) about the "connections between the mechanisms of cancer and COVID-19."

Events at the Intersection of Race and Science

Cultural Tax: The Cost of Being the Only or the Few

Tyrone Poster, a principal investigator at Boston University, shares insights on the "silent burden" that often accompanies being a Black STEM student and professional.

A Conversation with the Creators of The Nocturnists

The Nocturnists is a medical storytelling community founded by two UCSF physicians. Their audio documentary series "Stories from a Pandemic" and Black Voices in Healthcare" provide unique first-person accounts from health care workers.

Events for the Creature-Curious

Catch that Critter!

Ever wonder who or what is going bump in the night in your backyard? Here's your chance! Learn how to set up a "wildlife monitoring system and hear about the critters caught on camera at the Cal State East Bay Concord Campus and cameras set up in the Diablo hills. This first event will be a how-two and the second event will give participants the chance to share what they discovered.

A Very Spine-Tingling Spider Screening with KQEDs Deep Look

Yes, this one is a shameless plug! The team behind KQED's own Deep Look video series will present three of their popular spider episodes. Deep Look producers and cinematographers will reveal how they captured the spiders behavior on camera and spider experts will be on hand to answer all your arachnid-related questions.

And there are hundreds more events on all variety of subjects: storytelling and COVID, composting, wildfires. Check out the BASF website to see them all.

Editor's Note: KQED is a media sponsor of the Bay Area Science Festival.

Follow this link:
Bay Area Science Festival 2020: From Black Holes to Sourdough, It's All Virtual - KQED

Indias first indigenously developed test for coronavirus disease (Covid-19) based on the genetic editing tool CRISPR/Cas-9 is likely to be available in the market by the end of October. Heres everything that you need to know about the test:

Why is the test named Feluda?

Feluda is the acronym for FNCAS9 Editor Linked Uniform Detection Assay but the test is named after a fictional private detective from West Bengal created by the renowned writer and filmmaker Satyajit Ray.

Who has developed the test?

The test was developed by a research team led by Debojyoti Chakraborty and Souvik Maiti of the Council of Scientific and Industrial Research (CSIR) and researchers from the Institute of Genomics and Integrative Biology. It will be marketed by Tata Sons and has been approved by the Drug Controller General of India last month.

What is the effectiveness of the test?

It has a sensitivity of 96 per cent and specificity of 98 per cent which means that the test can detect positive and negative cases both up to 96 or 98 per cent of the time. The test matches the accuracy levels of RT- PCR tests which are widely being used for Covid- 19 diagnosis.

How does the test work?

With quicker result time and less expensive equipment, the test uses indigenously developed CRISPR gene-editing technology. It is the worlds first diagnostic test that uses specially adapted Cas9 protein to successfully detect the virus. It requires a nasal swab to be collected and sent to a lab. The Cas9 protein is barcoded to interact with the SARS-CoV2 sequence in the patients genetic material. The Cas9-SARS-CoV2 complex is then put on the paper strip, where using two lines (one control, one test), the test determines whether the sample was infected with Covid-19.

What is the CRISPR technology?

CRISPR, short form for Clustered Regularly Interspaced Short Palindromic Repeats, is a genome editing technology used in correcting genetic defects and treating and preventing the spread of diseases. The CRISPR technology that won the Nobel Prize for chemistry this year can detect specific sequences of DNA within a gene using an enzyme functioning as molecular scissors to snip it. It also allows researchers to easily alter DNA sequences and modify gene function.

What is the cost of the test?

The Feluda test is likely to cost about Rs 500 but the final cost will only be known once the test is commercially available. In contrast, the RT-PCR test now costs anywhere between Rs 1,600 to Rs 2,000.

Read the rest here:
What is the Feluda test that will be commercially available by October 31? - Hindustan Times

This report also researches and evaluates the impact of Covid-19 outbreak on the CRISPR & Cas Genes industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on CRISPR & Cas Genes and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Global CRISPR & Cas Genes Market Overview:

The research report, titled [Global CRISPR & Cas Genes Market 2020 by Company, Regions, Type and Application, Forecast to 2025], presents a detailed analysis of the drivers and restraints impacting the overall market. Analysts have studied the key trends defining the trajectory of the market. The research report also includes an assessment of the achievements made by the players in the global CRISPR & Cas Genes market so far. It also notes the key trends in the market that are likely to be lucrative. The research report aims to provide an unbiased and a comprehensive outlook of the global CRISPR & Cas Genes market to the readers.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2696251&source=atm

Global CRISPR & Cas Genes Market: Segmentation

For clearer understanding of the global CRISPR & Cas Genes market, analysts have segmented the market. The segmentation has been done on the basis of application, technology, and users. Each segment has been further explained with the help of graphs figures. This breakdown of the market gives the readers an objective view of the global CRISPR & Cas Genes market, which is essential to make sound investments.

The major players profiled in this report include:CRISPR TherapeuticsAstraZenecaAddgeneCaribou Biosciences, Inc.CellectisEditas Medicine, Inc.EgenesisF. Hoffmann-La Roche Ltd.Horizon Discovery Group PlcGenscripDanaher CorporationIntellia Therapeutics, Inc.LonzaMerck KGaANew England BioLabsTakara Bio, Inc.

To understand the changing political scenario, analysts have regionally segmented the market. This gives an overview of the political and socio-economic status of the regions that is expected to impact the market dynamic.

Global CRISPR & Cas Genes Market: Research Methodology

To begin with, the analysis has been put together using primary and secondary research methodologies. The information has been authenticated by market expert through valuable commentary. Research analysts have also conducted exhaustive interviews with market-relevant questions to collate this research report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2696251&source=atm

Global CRISPR & Cas Genes Market: Competitive Rivalry

The research report also studied the key players operating in the global CRISPR & Cas Genes market. It has evaluated and elucidated the research and development statuses of these companies, their financial outlooks, and their expansion plans for the forecast period. In addition, the research report also includes the list of strategic initiatives that clearly explain the achievements of the companies in the recent past.

The end users/applications and product categories analysis:On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-General Type

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of CRISPR & Cas Genes for each application, including-Biomedical

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2696251&licType=S&source=atm

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global CRISPR & Cas Genes market

Chapter 2: Evaluating the leading manufacturers of the global CRISPR & Cas Genes market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global CRISPR & Cas Genes market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

Contact Us:

marketresearchhub

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

About marketresearchhub

marketresearchhub is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

View post:
CRISPR & Cas Genes Market: Analysis and In-depth study on market Size Trends, Emerging Growth Factors and Regional Forecast to 2025 - Eurowire

MarketsandResearch.biz has released a recent industry research report titled Global CRISPR and Cas Genes Market 2020 by Company, Regions, Type and Application, Forecast to 2025 that spotlights on the study of past, present, and future look of the industry. The study conducted is inclusive of the industry trends and competitive and regional analysis covering the period 2020-2025. The report provides an actual industry viewpoint on market trends, dynamics for market growth rate, trading, growth rate, and revenue, in terms of demand and supply, cost structure, barriers, and challenges, product type, key market players, regions, and applications. Studying the market in terms of growth and expansion, the report covers the crucial factors influencing the global CRISPR and Cas Genes market.

Competitive Landscape:

The report analysts have identified direct or indirect market competitors, as well as comprehend their mission, vision, values, niche market, strengths, and weaknesses. The report provides Porters five forces including the threat of substitute products or services, established rivals, new entrants, and two others such as the bargaining power of suppliers and customers. Prominent players joined with their market share are highlighted in the report. The well-established players in the global CRISPR and Cas Genes market are: Synthego, OriGene Technologies, Inc., Addgene, Thermo Fisher Scientific, Inc., Transposagen Biopharmaceuticals, Inc., GenScript, Horizon Discovery Group Co., Integrated DNA Technologies, Inc., Merck, New England Biolabs, Cellecta, Inc., Agilent Technologies, Applied StemCell, Inc.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/107687

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

Geographical provincial information will help you in focusing on all the best-performing locales. The regions are extensively analyzed with respect to every parameter of the geographies in question, comprising, North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), MENA (Saudi Arabia, UAE, Turkey and South Africa)

In market segmentation by types, the report covers: Vector-based Cas, DNA-free Cas

In market segmentation by applications, the report covers the following uses: Genome Engineering, Disease Models, Others

The report evaluates production, consumption, and product segmentation highlights the current trend in the global market, and projects the revenue and potential developments of key players. Further, the report has analyzed the market concerning the regional landscape which incorporates extensive details about the types and application spectrums of this business. The research report tracks competitive growths such as joint ventures, tactical alliances, mergers and achievements, new product developments, and research and developments in the global CRISPR and Cas Genes market.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/107687/global-crispr-and-cas-genes-market-2020-by-company-regions-type-and-application-forecast-to-2025

Consumer Behavior Analysis:

Furthermore, the report analyzes the behavior of the CRISPR and Cas Genes consumers in the marketplace and looks at motives for those behavioral trends. Later, personal, and social consumer behavior is studied through focus groups, surveys, and tracking sales history. Our consumer behavior study helps businesses to understand consumers value. Not all consumers value the same benefits, so its important for businesses to segment their consumer base. Using the latest technology and analysis on the demand-side, key players are getting into consumer behavior and their changing preferences.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

Read more:
Global CRISPR and Cas Genes Market 2020 Trending Technologies, Developments, Key Players and End-use Industry to 2025 - Illadel Graff Supply

The latest adventure in food enhancement is CRISPR (e.g., clustered regularly interspaced short palindromic repeats/Cas9) gene-editing technology. It potentially has many major implications for enhanced global agriculture and much needed improvements in food security. CRISPR and gene editing tools simultaneously represents an extensive legal and regulatory challenge and additionally, a monumental scientific opportunity for the global food industry. With the development of genome editing technologies, the possibility of directly targeting and subsequently modifying genomic sequences in plants is intriguing. Genome editing can extend our ability to develop an extraordinary potential in applied biotechnology and its effects on increased world food production.

An important concept to the understanding of CRISPR/Cas came from scientific observations that the prokaryote repeat cluster (a family of DNA sequences found in the genomes ofprokaryoticorganisms such as bacteria and archaea) was incorporated into a set of homologous genes (having the same relation/structure or relative position) that make up CRISPR-associated systems orCasgenes.

TheCasproteins show nuclease and helicase motifs (a linkage that is found in a great many other DNA processing enzymes) which suggests an important role of the CRISPR loci. The development of programmable nucleases (e.g., clustered regularly interspaced short palindromic repeat (CRISPR)Cas-associated nucleases, zinc-finger nucleases (ZFNs), and transcription activator-like effector nucleases (TALENs)) has expedited the ability to improve the field of gene editing and subsequently potentially improve food production. CRISPR/Cas gene editing technology can potentially increase plant/crop yields and quality, plant drought resistance, herbicide and insecticide resistance, improved food safety and security, enhance the removal of antibiotic resistance (AMR), improve product shelf life and it can potentially accelerate the process of plant domestication.

Read more at Michigan State University (Scott Haskell)

Read more:
CRISPR and our food supply: What's next in feeding the world? - hortidaily.com

We think that its fair to say that the possibility of finding fantastic multi-year winners is what motivates many investors. Mistakes are inevitable, but a single top stock pick can cover any losses, and so much more. Take, for example, the CRISPR Therapeutics AG (NASDAQ:CRSP) share price, which skyrocketed 424% over three years. In more good news, the share price has risen 1.7% in thirty days.

View our latest analysis for CRISPR Therapeutics

We dont think that CRISPR Therapeutics modest trailing twelve month profit has the markets full attention at the moment. We think revenue is probably a better guide. As a general rule, we think this kind of company is more comparable to loss-making stocks, since the actual profit is so low. For shareholders to have confidence a company will grow profits significantly, it must grow revenue.

Over the last three years CRISPR Therapeutics has grown its revenue at 101% annually. Thats well above most pre-profit companies. And its not just the revenue that is taking off. The share price is up 74% per year in that time. Despite the strong run, top performers like CRISPR Therapeutics have been known to go on winning for decades. So wed recommend you take a closer look at this one, or even put it on your watchlist.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

CRISPR Therapeutics is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. So it makes a lot of sense to check out what analysts think CRISPR Therapeutics will earn in the future (free analyst consensus estimates)

Pleasingly, CRISPR Therapeutics total shareholder return last year was 163%. So this years TSR was actually better than the three-year TSR (annualized) of 74%. The improving returns to shareholders suggests the stock is becoming more popular with time. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, weve discovered 2 warning signs for CRISPR Therapeutics that you should be aware of before investing here.

But note: CRISPR Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

PromotedIf youre looking to trade CRISPR Therapeutics, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

Read this article:
Introducing CRISPR Therapeutics (NASDAQ:CRSP), The Stock That Soared 424% In The Last Three Years - Simply Wall St

LOS ANGELES, United States:The report titledGlobal CRISPR And CRISPR-Associated (Cas) Genes Marketis one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global CRISPR And CRISPR-Associated (Cas) Genes market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global CRISPR And CRISPR-Associated (Cas) Genes market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global CRISPR And CRISPR-Associated (Cas) Genes market is carefully analyzed and researched about by the market analysts.The market analysts and researchers have done extensive analysis of the global CRISPR And CRISPR-Associated (Cas) Genes market with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided accurate and reliable market data and useful recommendations with an aim to help the players gain an insight into the overall present and future market scenario. The CRISPR And CRISPR-Associated (Cas) Genes report comprises in-depth study of the potential segments including product type, application, and end user and their contribution to the overall market size.

In addition, market revenues based on region and country are provided in the CRISPR And CRISPR-Associated (Cas) Genes report. The authors of the report have also shed light on the common business tactics adopted by players. The leading players of the global CRISPR And CRISPR-Associated (Cas) Genes market and their complete profiles are included in the report. Besides that, investment opportunities, recommendations, and trends that are trending at present in the global CRISPR And CRISPR-Associated (Cas) Genes market are mapped by the report. With the help of this report, the key players of the global CRISPR And CRISPR-Associated (Cas) Genes market will be able to make sound decisions and plan their strategies accordingly to stay ahead of the curve.

Competitive landscape is a critical aspect every key player needs to be familiar with. The report throws light on the competitive scenario of the global CRISPR And CRISPR-Associated (Cas) Genes market to know the competition at both the domestic and global levels. Market experts have also offered the outline of every leading player of the global CRISPR And CRISPR-Associated (Cas) Genes market, considering the key aspects such as areas of operation, production, and product portfolio. Additionally, companies in the report are studied based on the key factors such as company size, market share, market growth, revenue, production volume, and profits.

Key Players Mentioned in the Global CRISPR And CRISPR-Associated (Cas) Genes Market Research Report:, Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)

http://qyresearch.com/sample-form/form/1514308/global-crispr-and-crispr-associated-cas-genes-industry

Segmental Analysis

The report has classified the globalCRISPR And CRISPR-Associated (Cas) Genesindustry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for theCRISPR And CRISPR-Associated (Cas) Genes manufacturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overallCRISPR And CRISPR-Associated (Cas) Genesindustry.

GlobalCRISPR And CRISPR-Associated (Cas) Genes Market Segment By Type:

, the CRISPR And CRISPR-Associated (Cas) Genes market is segmented into, Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering

GlobalCRISPR And CRISPR-Associated (Cas) Genes Market Segment By Application:

Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research and Development Institutes

The CRISPR And CRISPR-Associated (Cas) Genes Market report has been segregated based on distinct categories, such as product type, application, end user, and region. Each and every segment is evaluated on the basis of CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is estimated to generate opportunities in the global CRISPR And CRISPR-Associated (Cas) Genes market in the forthcoming years. This segmental analysis will surely turn out to be a useful tool for the readers, stakeholders, and market participants to get a complete picture of the global CRISPR And CRISPR-Associated (Cas) Genes market and its potential to grow in the years to come.

Key questions answered in the report:

In Order to place the Purchase Query Click Here at USD (4900): https://www.qyresearch.com/settlement/pre/4f61e33c3e4bba524a83d2f98fcdda9d,0,1,global-crispr-and-crispr-associated-cas-genes-industry

Table of Contents:

Table of Contents 1 Report Overview1.1 Research Scope1.2 Top CRISPR And CRISPR-Associated (Cas) Genes Manufacturers Covered: Ranking by Revenue1.3 Market Segment by Type

1.3.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)

1.3.2 Genome Editing

1.3.3 Genetic engineering

1.3.4 gRNA Database/Gene Librar

1.3.5 CRISPR Plasmid

1.3.6 Human Stem Cells

1.3.7 Genetically Modified Organisms/Crops

1.3.8 Cell Line Engineering1.4 Market Segment by Application

1.4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Consumption by Application: 2015 VS 2020 VS 2026

1.4.2 Biotechnology Companies

1.4.3 Pharmaceutical Companies

1.4.4 Academic Institutes

1.4.5 Research and Development Institutes1.5 Study Objectives1.6 Years Considered 2 Global Market Perspective2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue (2015-2026)

2.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue (2015-2026)

2.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Sales (2015-2026)2.2 CRISPR And CRISPR-Associated (Cas) Genes Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026

2.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales by Regions (2015-2020)

2.2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue by Regions (2015-2020)2.3 Global Top CRISPR And CRISPR-Associated (Cas) Genes Regions (Countries) Ranking by Market Size2.4 CRISPR And CRISPR-Associated (Cas) Genes Industry Trends

2.4.1 CRISPR And CRISPR-Associated (Cas) Genes Market Top Trends

2.4.2 Market Drivers

2.4.3 CRISPR And CRISPR-Associated (Cas) Genes Market Challenges 2.4.4 Porters Five Forces Analysis

2.4.5 Primary Interviews with Key CRISPR And CRISPR-Associated (Cas) Genes Players: Views for Future 3 Competitive Landscape by Manufacturers3.1 Global Top CRISPR And CRISPR-Associated (Cas) Genes Manufacturers by Sales (2015-2020)

3.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales by Manufacturers (2015-2020)

3.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Market Share by Manufacturers (2015-2020)

3.1.3 Global 5 and 10 Largest Manufacturers by CRISPR And CRISPR-Associated (Cas) Genes Sales in 20193.2 Global Top Manufacturers CRISPR And CRISPR-Associated (Cas) Genes by Revenue

3.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue by Manufacturers (2015-2020)

3.2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Share by Manufacturers (2015-2020)

3.2.3 Global CRISPR And CRISPR-Associated (Cas) Genes Market Concentration Ratio (CR5 and HHI)3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CRISPR And CRISPR-Associated (Cas) Genes as of 2019)3.4 Global CRISPR And CRISPR-Associated (Cas) Genes Average Selling Price (ASP) by Manufacturers3.5 Key Manufacturers CRISPR And CRISPR-Associated (Cas) Genes Plants/Factories Distribution and Area Served3.6 Date of Key Manufacturers Enter into CRISPR And CRISPR-Associated (Cas) Genes Market3.7 Key Manufacturers CRISPR And CRISPR-Associated (Cas) Genes Product Offered 3.8 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Historic Market Review by Type (2015-2020)

4.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Market Share by Type (2015-2020)

4.1.3 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2015-2020)

4.1.4 CRISPR And CRISPR-Associated (Cas) Genes Price by Type (2015-2020)4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Estimates and Forecasts by Type (2021-2026)

4.2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast by Type (2021-2026)

4.2.3 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast by Type (2021-2026)

4.2.4 CRISPR And CRISPR-Associated (Cas) Genes Price Forecast by Type (2021-2026) 5 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size by Application5.1 Global CRISPR And CRISPR-Associated (Cas) Genes Historic Market Review by Application (2015-2020)

5.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Market Share by Application (2015-2020)

5.1.3 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2015-2020)

5.1.4 CRISPR And CRISPR-Associated (Cas) Genes Price by Application (2015-2020)5.2 Global CRISPR And CRISPR-Associated (Cas) Genes Market Estimates and Forecasts by Application (2021-2026)

5.2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast by Application (2021-2026)

5.2.3 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast by Application (2021-2026)

5.2.4 CRISPR And CRISPR-Associated (Cas) Genes Price Forecast by Application (2021-2026) 6 North America6.1 North America CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Company6.2 North America CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Type6.3 North America CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Application6.4 North America CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Countries

6.4.1 North America CRISPR And CRISPR-Associated (Cas) Genes Sales by Countries

6.4.2 North America CRISPR And CRISPR-Associated (Cas) Genes Revenue by Countries

6.4.3 U.S.

6.4.4 Canada 7 Europe7.1 Europe CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Company7.2 Europe CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Type7.3 Europe CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Application7.4 Europe CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Countries

7.4.1 Europe CRISPR And CRISPR-Associated (Cas) Genes Sales by Countries

7.4.2 Europe CRISPR And CRISPR-Associated (Cas) Genes Revenue by Countries

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia 8 Asia Pacific8.1 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Company8.2 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Type8.3 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Application8.4 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Regions

8.4.1 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Sales by Regions

8.4.2 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Revenue by Regions

8.4.3 China

8.4.4 Japan

8.4.5 South Korea

8.4.6 India

8.4.7 Australia

8.4.8 Taiwan

8.4.9 Indonesia

8.4.10 Thailand

8.4.11 Malaysia

8.4.12 Philippines

8.4.13 Vietnam 9 Latin America9.1 Latin America CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Company9.2 Latin America CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Type9.3 Latin America CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Application9.4 Latin America CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Countries

9.4.1 Latin America CRISPR And CRISPR-Associated (Cas) Genes Sales by Countries

9.4.2 Latin America CRISPR And CRISPR-Associated (Cas) Genes Revenue by Countries

9.4.3 Mexico

9.4.4 Brazil

9.4.5 Argentina 10 Middle East and Africa10.1 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Type10.2 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Application10.3 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Breakdown Data by Countries

10.3.1 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Sales by Countries

10.3.2 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Revenue by Countries

10.3.3 Turkey

10.3.4 Saudi Arabia

10.3.5 U.A.E 11 Company Profiles11.1 Caribou Biosciences

11.1.1 Caribou Biosciences Corporation Information

11.1.2 Caribou Biosciences Business Overview and Total Revenue (2019 VS 2018)

11.1.3 Caribou Biosciences CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)

11.1.4 Caribou Biosciences CRISPR And CRISPR-Associated (Cas) Genes Products and Services

11.1.5 Caribou Biosciences SWOT Analysis

11.1.6 Caribou Biosciences Recent Developments11.2 Addgene

11.2.1 Addgene Corporation Information

11.2.2 Addgene Business Overview and Total Revenue (2019 VS 2018)

11.2.3 Addgene CRISPR And CRISPR-Associated (Cas) Genes Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)

See the rest here:
CRISPR And CRISPR-Associated (Cas) Genes Market Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast by...

CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have announced that the European Medicines Agency has granted their experimental, autologous, ex vivo CRISPR/Cas9 gene-edited therapy, CTX001 Priority Medicines designation. The therapy has been granted PRIME designation for severe sickle cell disease treatment.

The PRIME designation is a regulatory mechanism that offers early and proactive support to promising medicines developers to enhance development plans. Also, it accelerates the evaluation of medicines under development to reach patients as soon as possible. PRIMEs objective is to ensure patients benefit fasters from new proprietary therapies that have shown the potential of addressing a significant unmet medical need. The companies received the PRIME designation based on data from their on-going phase 1/2 study of CTX001 in treating severe sickle cell disease patients.

CTX001 is currently being investigated to treat patients with severe SCD or transfusion-dependent beta-thalassemia, whereby hematopoietic stem cells are purposed to produce high fetal hemoglobin levels in red cells. HbF is an oxygen-carrying hemoglobin form present naturally at birth, which later switches to adult hemoglobin form. HbF elevation by CTX001 can potentially alleviate transfusion requirements for TDT patients and minimize painful and devastating sickle crises in patients with SCD.

So far, CTX001 has received Regenerati9ve Medicine Advanced Therapy (RMAT), Orphan Drug Designation, and Fast Track designation from the FDA. Also, CTX001 has Orphan Drug Designation from the European Commission for SCD and TDT.

CRISPR Therapeutics and Vertex are developing CTX001 under a co-development and co-commercialization agreement. So far, CTX001 is the most progressive gene editing therapy under development for SCD and TDT. The companies entered a strategic collaboration agreement in 2015 intending to use CRISPR/Cas9 to develop and discover novel therapies for the treatment of underlying genetic causes of diseases. CTX001 is the first joint treatment to emerge from the collaboration, and all development costs and profits will be shared.

Read this article:
CRISPR Therapeutics (NASDAQ:CRSP) and Vertex (NASDAQ:VRTX) Receive Priority Medicines (PRIME) Designation From EMA For CTX001 In SCD - BP Journal

Emmanuelle Charpentier and Jennifer Doudna have been given the 2020 Nobel Prize in Chemistry for their discovery and development of CRISPR-Cas9 genome editing.

The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry 2020 to Emmanuelle Charpentier of the Max Planck Unit for the Science of Pathogens, Germany, and Jennifer Doudna of the University of California, Berkeley, US. The Nobel Prize is for the development of CRISPR-Cas9, a method for genome editing.

According to the Royal Swedish Academy of Sciences, Emmanuelle Charpentier and Jennifer Doudna discovered the CRISPR-Cas9 genetic scissors. Using these, researchers can change the DNA of animals, plants and microorganisms with extremely high precision. This technology has had a revolutionary impact on the life sciences, is contributing to new cancer therapies and may aid in curing inherited diseases.

Also, using the CRISPR-Cas9 genetic scissors, it is now possible to change DNA over the course of a few weeks. This used to be time-consuming, difficult and sometimes impossible work.

There is enormous power in this genetic tool, which affects us all. It has not only revolutionised basic science, but also resulted in innovative crops and will lead to ground-breaking new medical treatments, said Claes Gustafsson, chair of the Nobel Committee for Chemistry.

The discovery of CRISPR-Cas9 was made during Emmanuelle Charpentiers studies of Streptococcus pyogenes, one of the bacteria that cause the most harm to humanity. She discovered a previously unknown molecule, tracrRNA. Her work showed that tracrRNA is part of bacterias ancient immune system, CRISPR-Cas, that disarms viruses by cleaving their DNA.Charpentier published her discovery in 2011. The same year, she initiated a collaboration with Jennifer Doudna, an experienced biochemist with vast knowledge of RNA. Together, they succeeded in recreating the bacterias genetic scissors in a test tube and simplifying the scissors molecular components so they were easier to use.

In another experiment, they then reprogrammed the genetic scissors. In their natural form, the scissors recognise DNA from viruses, but Charpentier and Doudna proved that they could be controlled so that they can cut any DNA molecule at a predetermined site.

The academy highlights that since Charpentier and Doudna discovered the CRISPR-Cas9 genetic scissors in 2012 their use has exploded. This tool has contributed to many important discoveries in basic research and clinical trials of new cancer therapies are underway.

Continued here:
Nobel Prize in Chemistry awarded to discoverers of CRISPR-Cas9 - Drug Target Review